QUALITATIVE RESEARCH IN HAEMOPHILIA A: EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

被引：1
|
作者：
Lambert, T. [1 ]
Rothschild, C. [2 ]
Baillon, N. [3 ]
Gaudin, H. [4 ]
Acquadro, M. [5 ]
Arnould, B. [5 ]
Lambert, J. [5 ]
Negrier, C. [6 ]
机构：
[1] Hop Bicetre, AP HP, Le Kremlin Bicetre, France
[2] Hop Necker Enfants Malad, Paris, France
[3] Roche SAS, Boulogne, France
[4] Chugai Pharma France, Puteaux La Defense, France
[5] Mapi, Lyon, France
[6] CHU Lyon, HCL, Bron, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2921
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY223
引用
收藏
页码：S474 / S474
页数：1
相关论文
共 50 条
  • [21] First report of emicizumab use in a patient with severe haemophilia A and high-titer inhibitor in Uruguay
    Berro, Maximiliano
    Insagaray, Juan
    Rodriguez, Ismael
    ANALES DE LA FACULTAD DE MEDICINA-UNIVERSIDAD DE LA REPUBLICA URUGUAY, 2020, 7 (02):
  • [22] Prophylaxis with emicizumab in 50 children and adolescents with severe haemophilia A without inhibitor in Uruguay: National experience
    Lemos, Felipe
    Petraccia, Carlos
    Laura Fraga, Maria
    Gomez, Rosario
    Lutz, Stefani
    Laura Casuriaga, Ana
    Inguanzo, Marianella
    Gonzalez, Jimena
    Echeverria, Silvina
    Gomez, Florencia
    Arocena, Maria
    Gonzalez, Yenirellys
    Giachetto, Gustavo
    Boggia, Beatriz
    HAEMOPHILIA, 2024, 30 : 96 - 97
  • [23] Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India
    Bansal, Shweta
    Donners, Anouk A. M. T.
    Fischer, Kathelijn
    Kshirsagar, Shrinath
    Rangarajan, Savita
    Phadke, Varsha
    Mhatre, Shrutika
    Sontate, Bharati
    D'silva, Magdelene
    Ansari, Shahana
    Shetty, Shrimati
    HAEMOPHILIA, 2023, 29 (03) : 931 - 934
  • [24] Emicizumab dose capping in obese patients with Haemophilia A: Early outcomes at a single centre
    Krumb, Evelien
    Lambert, Catherine
    Hermans, Cedric
    HAEMOPHILIA, 2022, 28 (06) : E245 - E247
  • [25] Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors
    Roman, Maria Teresa Alvarez
    Kragh, Nana
    Guyot, Patricia
    Wilson, Amanda
    Wojciechowski, Piotr
    Margas, Wojciech
    Wdowiak, Marlena
    Santagostino, Elena
    Arnaud, Alix
    ADVANCES IN THERAPY, 2025, 42 (01) : 442 - 455
  • [26] Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study
    Al-Samkari, Hanny
    Croteau, Stacy E.
    HAEMOPHILIA, 2021, 27 (02) : E270 - E273
  • [27] Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis
    Batsuli, Glaivy
    Zimowski, Karen L.
    Tickle, Kelly
    Meeks, Shannon L.
    Sidonio, Robert F., Jr.
    HAEMOPHILIA, 2019, 25 (05) : 789 - 796
  • [28] Real-world cost estimates of initiating emicizumab in US patients with haemophilia A
    Samelson-Jones, Benjamin J.
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Raffini, Leslie
    HAEMOPHILIA, 2021, 27 (04) : 591 - 598
  • [29] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL
    Soares, V
    Freitas, L. A.
    Cafe, A.
    VALUE IN HEALTH, 2019, 22 : S905 - S905
  • [30] Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors
    Brophy, Donald F.
    Martin, Erika J.
    Kuhn, Janice
    HAEMOPHILIA, 2019, 25 (02) : E121 - E123
12345